603087 甘李药业
已收盘 08-18 15:00:00
资讯
新帖
简况
甘李药业（603087）披露首次公开发行部分限售股上市流通公告，8月18日股价下跌2.21%
证券之星 · 08-18 22:05
甘李药业（603087）披露首次公开发行部分限售股上市流通公告，8月18日股价下跌2.21%
每周股票复盘：甘李药业（603087）获6200万欧元首付款
证券之星 · 08-16
每周股票复盘：甘李药业（603087）获6200万欧元首付款
甘李药业高管集体减持背后：业绩踩线达成暗藏财技 胰岛素增长触顶、GLP-1 管线突围阻力重重
新浪证券 · 08-14
甘李药业高管集体减持背后：业绩踩线达成暗藏财技 胰岛素增长触顶、GLP-1 管线突围阻力重重
前脚“组团”减持、后脚7.26亿欧元合作落地，甘李药业“利好与争议齐飞”
蓝鲸财经 · 08-12
前脚“组团”减持、后脚7.26亿欧元合作落地，甘李药业“利好与争议齐飞”
研报掘金丨平安证券：维持甘李药业“推荐”评级，创新管线稳步推进
格隆汇 · 08-12
研报掘金丨平安证券：维持甘李药业“推荐”评级，创新管线稳步推进
吃药行情继续上演！甘李药业涨停，百济神州6连阳！华宝基金港股通医疗ETF、港股通创新药ETF逆市三连涨！
新浪基金 · 08-11
吃药行情继续上演！甘李药业涨停，百济神州6连阳！华宝基金港股通医疗ETF、港股通创新药ETF逆市三连涨！
8月11日甘李药业创60日新高，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 08-11
8月11日甘李药业创60日新高，招商国证生物医药指数(LOF)C基金重仓该股
异动快报：甘李药业（603087）8月11日9点33分触及涨停板
证券之星 · 08-11
异动快报：甘李药业（603087）8月11日9点33分触及涨停板
百济神州与Revolution Medicines宣布合作；甘李药业宣布减肥新药海外BD | 医药早参
每日经济新闻 · 08-11
百济神州与Revolution Medicines宣布合作；甘李药业宣布减肥新药海外BD | 医药早参
甘李药业(603087.SH)与Menarini公司签署博凡格鲁肽项目授权许可协议
智通财经 · 08-10
甘李药业(603087.SH)与Menarini公司签署博凡格鲁肽项目授权许可协议
甘李药业最新公告：授权Menarini在欧盟27国等地区的博凡格鲁肽超重或肥胖适应症的商业化权利里程碑付款累计最高可达6.64亿欧元
证券之星 · 08-10
甘李药业最新公告：授权Menarini在欧盟27国等地区的博凡格鲁肽超重或肥胖适应症的商业化权利里程碑付款累计最高可达6.64亿欧元
股市必读：甘李药业新发布《董事、高级管理人员减持股份计划公告》
证券之星 · 08-10
股市必读：甘李药业新发布《董事、高级管理人员减持股份计划公告》
每周股票复盘：甘李药业（603087）多名高管拟减持合计不超0.02%股份
证券之星 · 08-09
每周股票复盘：甘李药业（603087）多名高管拟减持合计不超0.02%股份
甘李药业（603087）披露限制性股票回购注销实施公告，8月7日股价上涨2.18%
证券之星 · 08-07
甘李药业（603087）披露限制性股票回购注销实施公告，8月7日股价上涨2.18%
甘李药业（603087）披露董事及高管减持股份计划公告，8月6日股价下跌3.12%
证券之星 · 08-06
甘李药业（603087）披露董事及高管减持股份计划公告，8月6日股价下跌3.12%
每周股票复盘：甘李药业（603087）完成63万限制性股票授予
证券之星 · 08-02
每周股票复盘：甘李药业（603087）完成63万限制性股票授予
甘李药业（603087）披露2026年限制性股票激励计划授予登记完成公告，7月28日股价下跌0.17%
证券之星 · 07-28
甘李药业（603087）披露2026年限制性股票激励计划授予登记完成公告，7月28日股价下跌0.17%
7月24日甘李药业跌5.03%，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 07-24
7月24日甘李药业跌5.03%，招商国证生物医药指数(LOF)C基金重仓该股
甘李药业：将在后续会议材料中增加“交通出行指引”板块
证券之星 · 07-21
甘李药业：将在后续会议材料中增加“交通出行指引”板块
甘李药业（603087）披露向2026年限制性股票激励计划激励对象授予限制性股票的公告，7月15日股价下跌0.44%
证券之星 · 07-15
甘李药业（603087）披露向2026年限制性股票激励计划激励对象授予限制性股票的公告，7月15日股价下跌0.44%
加载更多
公司概况
公司名称：
甘李药业股份有限公司
所属行业：
医药制造业
上市日期：
2020-06-29
主营业务：
甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是甘精胰岛素注射液、赖脯胰岛素注射液、精蛋白锌重组赖脯胰岛素混合注射液、门冬胰岛素注射液、门冬胰岛素30注射液、精蛋白人胰岛素混合注射液。
发行价格：
63.32
{"stockData":{"symbol":"603087","market":"SH","secType":"STK","nameCN":"甘李药业","latestPrice":72.58,"timestamp":1787036400000,"preClose":74.22,"halted":0,"volume":13369957,"delay":0,"changeRate":-0.0221,"floatShares":561000000,"shares":597000000,"eps":1.7143,"marketStatus":"已收盘","change":-1.64,"latestTime":"08-18 15:00:00","open":74,"high":74.3,"low":72.11,"amount":975000000,"amplitude":0.0295,"askPrice":72.58,"askSize":699,"bidPrice":72.57,"bidSize":13,"shortable":0,"etf":0,"ttmEps":1.7143,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787103000000},"marketStatusCode":5,"adr":0,"adjPreClose":74.22,"symbolType":"stock","openAndCloseTimeList":[[1787016600000,1787023800000],[1787029200000,1787036400000]],"highLimit":81.64,"lowLimit":66.8,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":597432169,"isCdr":false,"pbRate":3.67,"roa":"--","peRate":42.337981,"roe":"1.64%","epsLYR":1.93,"committee":-0.670146,"marketValue":43362000000,"turnoverRate":0.0238,"status":1,"floatMarketCap":40729000000},"requestUrl":"/m/hq/s/603087","defaultTab":"news","newsList":[{"id":"2660498476","title":"甘李药业（603087）披露首次公开发行部分限售股上市流通公告，8月18日股价下跌2.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660498476","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660498476?lang=zh_cn&edition=full","pubTime":"2026-08-18 22:05","pubTimestamp":1787061917,"startTime":"0","endTime":"0","summary":"近日，甘李药业股份有限公司发布首次公开发行部分限售股上市流通公告，本次上市流通的限售股为首次公开发行限售股，数量为259,327股，占公司总股本的0.0434%，涉及股东为南京铸成顺康创业投资合伙企业。本次限售股上市流通日期为2026年8月24日。截至公告披露日，相关股东已履行承诺，股份解除限售条件满足，保荐机构对本次限售股解禁无异议。公司总股本为597,432,169股，本次变动后有限售条件流通股减少至36,015,582股，无限售条件流通股相应增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800042164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659175914","title":"每周股票复盘：甘李药业（603087）获6200万欧元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2659175914","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659175914?lang=zh_cn&edition=full","pubTime":"2026-08-16 01:38","pubTimestamp":1786815491,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，甘李药业报收于74.98元，较上周的69.69元上涨7.59%。本周，甘李药业8月12日盘中最高价报79.99元。甘李药业当前最新总市值447.95亿元，在生物制品板块市值排名2/51，在两市A股市值排名452/5207。公司获6,200万欧元首付款，累计最高可达6.64亿欧元的里程碑付款，以及按最高双位数比例支付的特许权使用费。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","EUO","BK0239","MEURmain","FXE","EURmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659197132","title":"甘李药业高管集体减持背后：业绩踩线达成暗藏财技 胰岛素增长触顶、GLP-1 管线突围阻力重重","url":"https://stock-news.laohu8.com/highlight/detail?id=2659197132","media":"新浪证券","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659197132?lang=zh_cn&edition=full","pubTime":"2026-08-14 12:04","pubTimestamp":1786680240,"startTime":"0","endTime":"0","summary":"胰岛素增长触顶GLP-1 管线突围阻力重重业务方面，甘李药业近年业绩的核心驱动力，来自胰岛素国家集采带来的市场份额提升。其中甘李药业三代胰岛素采购量占比约32%，诺和诺德约27%，通化东宝、礼来、赛诺菲、联邦制药分别约占11%、11%、10%、9%。甘李药业已稳居国产胰岛素龙头位置，进一步大幅提升份额的空间已相对有限。胰岛素业务的高增长不具备长期可持续性，GLP-1创新药虽有想象空间，但面临激烈竞争，最终兑现程度存在较大不确定性。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-08-14/doc-ininhaiq4220621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["JDOC","BK4144","603087","GLP","BK4590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658430970","title":"前脚“组团”减持、后脚7.26亿欧元合作落地，甘李药业“利好与争议齐飞”","url":"https://stock-news.laohu8.com/highlight/detail?id=2658430970","media":"蓝鲸财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658430970?lang=zh_cn&edition=full","pubTime":"2026-08-12 21:05","pubTimestamp":1786539908,"startTime":"0","endTime":"0","summary":"8月12日延续涨势，截至收盘，甘李药业报77.20元，当日上涨3.67%，振幅达9.05%，成交量3883万股，换手率6.92%，最新市值461亿元。自今年5月27日以来，甘李药业股价累计涨幅达46%。随着甘李药业近期股价持续上涨，“高管借利好套现”的质疑声也没停过。此外，通过此次交易，甘李药业实现了风险外溢，固定成本转移。高管敏感时间点“组团减持”引争议相比此次合作未来的隐忧，当下高管减持带来的争议似乎更需要公司重视。前述投资者表示。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1786539404861209942","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["NBIE","603087","BK0239","FXE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658924373","title":"研报掘金丨平安证券：维持甘李药业“推荐”评级，创新管线稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2658924373","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658924373?lang=zh_cn&edition=full","pubTime":"2026-08-12 15:02","pubTimestamp":1786518163,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["161027","BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992720","title":"吃药行情继续上演！甘李药业涨停，百济神州6连阳！华宝基金港股通医疗ETF、港股通创新药ETF逆市三连涨！","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992720","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658992720?lang=zh_cn&edition=full","pubTime":"2026-08-11 19:25","pubTimestamp":1786447500,"startTime":"0","endTime":"0","summary":"8月11月，A股、港股大幅回调，医药资产受大市影响整体冲高回落，其中创新药产业链韧性凸显，批量成功收红。成份股再鼎医药领涨5.28%，权重龙头百济神州涨2.63%斩获6连阳，股价创年内新高！基金管理人评估的药ETF华宝的风险等级为R3-中风险，适宜平衡型及以上的投资者，港股通医疗ETF华宝、港股通创新药ETF华宝及其联接基金的风险等级为R4-中高风险，适宜积极型及以上的投资者。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-11/doc-inimyaaf7389173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1588","LU1719994722.HKD","LU1770034418.SGD","KURE","06160","BK4588","603087","BK4526","BK4139","ONC","LU1969619763.USD","LU1251922891.USD","LU0228659784.USD","LU0588546209.SGD","BK1161","BK1500","159316","BK4585","LU0828237510.HKD","LU1303224171.USD","FLHK","BK0239","159828","BK1583","LU2328871848.SGD","LU0307460666.USD","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658192993","title":"8月11日甘李药业创60日新高，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658192993","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658192993?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:33","pubTimestamp":1786437227,"startTime":"0","endTime":"0","summary":"根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共30家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为15.39亿元，最新净值0.4263，较上一交易日上涨1.52%，近一年上涨0.0%。招商国证生物医药指数C的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100025962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087","161726","399441"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658655609","title":"异动快报：甘李药业（603087）8月11日9点33分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2658655609","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658655609?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:36","pubTimestamp":1786412185,"startTime":"0","endTime":"0","summary":"证券之星8月11日盘中消息，9点33分甘李药业（603087）触及涨停板。其所属行业生物制品目前上涨。领涨股为百普赛斯。该股为减肥药，创新药，化学原料药概念热股，当日减肥药概念上涨0.28%。8月10日的资金流向数据方面，主力资金净流出5420.11万元，占总成交额6.22%，游资资金净流入1102.23万元，占总成交额1.26%，散户资金净流入4317.88万元，占总成交额4.95%。近5日资金流向一览见下表：甘李药业主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100008155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950539","title":"百济神州与Revolution Medicines宣布合作；甘李药业宣布减肥新药海外BD | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950539","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658950539?lang=zh_cn&edition=full","pubTime":"2026-08-11 07:01","pubTimestamp":1786402877,"startTime":"0","endTime":"0","summary":"丨2026年8月11日星期二丨NO.1百济神州与RevolutionMedicines宣布达成临床开发及区域商业化合作8月10日，百济神州宣布与全球专注癌症药物研发的生物科技公司RevolutionMedicines达成一项多方面合作协议，涵盖临床联合开发与区域商业化授权两大核心板块，旨在加速RAS驱动型癌症的创新疗法研发与市场落地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837029212.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837029212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0228659784.USD","IE00B2B36J28.USD","BK1500","BK1161","BK4139","09939","IE00BJT1NW94.SGD","IE0009355771.USD","LU0588546209.SGD","IE00BJJMRZ35.SGD","LU1303224171.USD","BK0239","LU1770034418.SGD","RVMD","LU0307460666.USD","IE0002141913.USD","BK4588","06160","LU1719994722.HKD","IE00BFTCPJ56.SGD","LU0828237510.HKD","LU1969619763.USD","IDNA","688235","KURE","PTH","IE0009354923.USD","BBH","BK4526","BK1583","603087","LU2328871848.SGD","LU0109394709.USD","159938","BK1588","CANC","BK1515","IE00B4R5TH58.HKD","BK4585","ONC","LU1251922891.USD","BD","LU0889565916.HKD","BK1574","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658173982","title":"甘李药业(603087.SH)与Menarini公司签署博凡格鲁肽项目授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2658173982","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658173982?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:56","pubTimestamp":1786355774,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业 发布公告，近日，公司与Menarini达成独家许可协议，授予Menarini在公司自主研发的博凡格鲁肽超重或肥胖适应症项目在授权区域内的上市注册及商业化的权利。博凡格鲁肽作为潜在的全球首款GLP-1RA双周制剂，若协议顺利履行，将进一步丰富全球肥胖症患者的用药选择，提升优质药物的可及性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658847769","title":"甘李药业最新公告：授权Menarini在欧盟27国等地区的博凡格鲁肽超重或肥胖适应症的商业化权利里程碑付款累计最高可达6.64亿欧元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658847769","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658847769?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:38","pubTimestamp":1786354690,"startTime":"0","endTime":"0","summary":"甘李药业(603087.SH)公告称，公司与Menarini达成独家许可协议，授予其在欧盟27国及英国等39个欧洲国家和地区博凡格鲁肽超重或肥胖适应症的上市注册及商业化权利。Menarini将支付不可退还首付款6200万欧元，里程碑付款累计最高可达6.64亿欧元，商业化后按最高双位数比例支付梯度特许权使用费。博凡格鲁肽是公司自主研发的每两周给药一次的GLP-1RA，有望成为全球首款上市的GLP-1RA双周制剂。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000022822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087","EURmain","EUO","FESXmain","MEURmain","FXE","FSXEmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658670268","title":"股市必读：甘李药业新发布《董事、高级管理人员减持股份计划公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658670268","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658670268?lang=zh_cn&edition=full","pubTime":"2026-08-10 01:42","pubTimestamp":1786297331,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，甘李药业报收于69.69元，上涨2.18%，换手率2.29%，成交量12.84万手，成交额8.85亿元。公司公告汇总：董事长陈伟等7名董监高拟自8月31日起3个月内合计减持不超过公司总股本0.02%的股份，用于偿还个人债务。公司公告汇总：甘李药业拟于2026年8月12日完成502,800股限制性股票回购注销，其中21,000股因司法冻结暂未注销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658730546","title":"每周股票复盘：甘李药业（603087）多名高管拟减持合计不超0.02%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2658730546","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658730546?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:12","pubTimestamp":1786212733,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，甘李药业报收于69.69元，较上周的68.73元上涨1.4%。本周，甘李药业8月5日盘中最高价报71.13元。上述人员计划自公告发布之日起满15个交易日后3个月内，通过集中竞价方式各自减持不超过120,000股，即不超过其持股数量的23.077%，合计减持比例不超过公司总股本的0.02%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657644673","title":"甘李药业（603087）披露限制性股票回购注销实施公告，8月7日股价上涨2.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657644673","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657644673?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:20","pubTimestamp":1786112442,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，甘李药业报收于69.69元，较前一交易日上涨2.18%，最新总市值为416.7亿元。近日，甘李药业发布《关于2022年、2024年限制性股票激励计划部分限制性股票回购注销实施公告》。公告显示，因部分激励对象离职或绩效考核未达标，公司拟回购注销2022年及2024年限制性股票激励计划中31名激励对象已获授但未达解除限售条件的限制性股票共计502,800股。注销登记预计于2026年8月12日完成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700041051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657555630","title":"甘李药业（603087）披露董事及高管减持股份计划公告，8月6日股价下跌3.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657555630","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657555630?lang=zh_cn&edition=full","pubTime":"2026-08-06 22:11","pubTimestamp":1786025473,"startTime":"0","endTime":"0","summary":"截至2026年8月6日收盘，甘李药业报收于68.2元，较前一交易日下跌3.12%，最新总市值为407.79亿元。该股当日开盘70.4元，最高70.79元，最低68.01元，成交额达6.03亿元，换手率为1.56%。近日，甘李药业披露《董事、高级管理人员减持股份计划公告》。上述人员计划自公告发布之日起满15个交易日后3个月内，通过集中竞价方式各自减持不超过120,000股，即不超过其持股数量的23.077%，合计减持比例不超过公司总股本的0.02%。减持期间为2026年8月31日至2026年11月30日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600039777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656331968","title":"每周股票复盘：甘李药业（603087）完成63万限制性股票授予","url":"https://stock-news.laohu8.com/highlight/detail?id=2656331968","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656331968?lang=zh_cn&edition=full","pubTime":"2026-08-02 03:18","pubTimestamp":1785611894,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，甘李药业报收于68.73元，较上周的63.3元上涨8.58%。本周，甘李药业7月31日盘中最高价报69.49元。甘李药业当前最新总市值410.96亿元，在生物制品板块市值排名2/51，在两市A股市值排名455/5202。本周关注点公司公告汇总：甘李药业完成63万股限制性股票授予登记，占总股本0.1055%。本次授予完成后，公司总股本由597,304,909股增至597,934,969股，有限售条件股份相应增加63万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200001052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654888798","title":"甘李药业（603087）披露2026年限制性股票激励计划授予登记完成公告，7月28日股价下跌0.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654888798","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654888798?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:20","pubTimestamp":1785248429,"startTime":"0","endTime":"0","summary":"截至2026年7月28日收盘，甘李药业报收于64.58元，较前一交易日下跌0.17%，最新总市值为386.15亿元。公告显示，公司于2026年7月27日完成2026年限制性股票激励计划的授予登记，登记数量为63万股，占公司总股本的0.1055%。本次授予完成后，公司总股本由597,304,969股增至597,934,969股，有限售条件股份相应增加63万股。激励计划有效期不超过48个月，设两个解除限售期，分别在登记完成后的12个月和24个月后解除限售，每次解除限售比例为50%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800039823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653046707","title":"7月24日甘李药业跌5.03%，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653046707","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653046707?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:37","pubTimestamp":1784882270,"startTime":"0","endTime":"0","summary":"证券之星消息，7月24日甘李药业跌5.03%，收盘报63.3元，换手率1.86%，成交量10.45万手，成交额6.74亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共30家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为15.39亿元，最新净值0.3974，较上一交易日下跌0.5%，近一年下跌3.29%。招商国证生物医药指数C的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","161726","BK0239","399441"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653275141","title":"甘李药业：将在后续会议材料中增加“交通出行指引”板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2653275141","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653275141?lang=zh_cn&edition=full","pubTime":"2026-07-21 18:03","pubTimestamp":1784628184,"startTime":"0","endTime":"0","summary":"证券之星消息，甘李药业07月21日在投资者关系平台上答复投资者关心的问题。我建议每次股东会或业绩发布会公司能安排车辆从主要地铁站或公交站点接送参会人员，以体现对参会人员的重视，谢谢。我们将在后续会议材料中增加 “交通出行指引” 板块，为有需要的投资者提供出行指引。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100033738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651267469","title":"甘李药业（603087）披露向2026年限制性股票激励计划激励对象授予限制性股票的公告，7月15日股价下跌0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651267469","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651267469?lang=zh_cn&edition=full","pubTime":"2026-07-15 22:04","pubTimestamp":1784124261,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘，甘李药业报收于69.69元，较前一交易日下跌0.44%，最新总市值为416.26亿元。近日，甘李药业股份有限公司召开第五届董事会第十次会议，审议通过向2026年限制性股票激励计划激励对象授予限制性股票的议案，确定2026年7月15日为授予日，向20名激励对象授予63万股限制性股票，授予价格为27.80元/股。本次激励计划有效期不超过48个月，限售期分别为12个月和24个月，解除限售比例各为50%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500044490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787087014905,"stockEarnings":[{"period":"1week","weight":-0.0254},{"period":"1month","weight":0.1293},{"period":"3month","weight":0.3413},{"period":"6month","weight":0.1382},{"period":"1year","weight":0.1629},{"period":"ytd","weight":0.0867}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":0.0601},{"period":"3month","weight":-0.0413},{"period":"6month","weight":-0.0225},{"period":"1year","weight":0.0704},{"period":"ytd","weight":0.0054}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"甘李药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"81965人(较上一季度减少5.45%)","perCapita":"6849股","listingDate":"2020-06-29","address":"北京市通州区漷县镇南凤西一路8号","registeredCapital":"59743万元","survey":" 甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是甘精胰岛素注射液、赖脯胰岛素注射液、精蛋白锌重组赖脯胰岛素混合注射液、门冬胰岛素注射液、门冬胰岛素30注射液、精蛋白人胰岛素混合注射液。","listedPrice":63.32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"甘李药业(603087)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供甘李药业(603087)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"甘李药业,603087,甘李药业股票,甘李药业股票老虎,甘李药业股票老虎国际,甘李药业行情,甘李药业股票行情,甘李药业股价,甘李药业股市,甘李药业股票价格,甘李药业股票交易,甘李药业股票购买,甘李药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"甘李药业(603087)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供甘李药业(603087)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}